The new third-generation cephalosporins have an improved antibacterial spectrum and are agents of choice for the treatment of many gram-negative pathogens. With the introduction of these cephalosporins, questions on their indications and use need to be considered. It is especially important that they be saved for special situations in which their capabilities are required, which will prevent the development of widespread resistance and superinfection. A clinical summary of the new cephalosporins is provided, with emphasis on the situations in which they are agents of choice.